Australia is welcome potentially transformative medication for weight issues: Retatrutide. The dual agonist – acting on both GLP-1 and GIP receptors – has remarkable efficacy in global trials, indicating considerable reductions in BMI. While approval hasn't occurred with TGA, several Australians